Lorne Zinman

Low-intensity laser therapy for painful symptoms of diabetic sensorimotor polyneuropathy: a controlled trial.

Cooling detection thresholds in the assessment of diabetic sensory polyneuropathy: comparison of CASE IV and Medoc instruments.

Sensitivity of repetitive facial-nerve stimulation in patients with myasthenia gravis.

IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial.

Genetic studies of GRN and IFT74 in amyotrophic lateral sclerosis.

Surrogate therapeutic outcome measures in patients with myasthenia gravis.

Evidence that TDP-43 is not the major ubiquitinated target within the pathological inclusions of amyotrophic lateral sclerosis.

IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies.

Are statin medications safe in patients with ALS?

Lack of evidence of monomer/misfolded superoxide dismutase-1 in sporadic amyotrophic lateral sclerosis.

Kinematics of disease progression in bulbar ALS.

Safety of influenza vaccination in patients with myasthenia gravis: a population-based study.

Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form.

Non-invasive ventilation for Canadian patients with ALS: do we have consensus?

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.

Distinct biochemical signatures characterize peripherin isoform expression in both traumatic neuronal injury and motor neuron disease.

RNA targets of TDP-43 identified by UV-CLIP are deregulated in ALS.

Emerging targets and treatments in amyotrophic lateral sclerosis.

Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and mutation.

Paraspinal myopathy with novel shard-like compact aggregates of thin filaments.

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Tongue movements and their acoustic consequences in amyotrophic lateral sclerosis.

Investigation of C9orf72 in 4 Neurodegenerative Disorders.

Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis.

Mortality associated with periodic limb movements during sleep in amyotrophic lateral sclerosis patients.

Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion.

Bulbar and speech motor assessment in ALS: Challenges and future directions.

Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis.

Venous thromboembolism in amyotrophic lateral sclerosis: a prospective study.

Hypermethylation of the CpG-island near the C9orf72 G₄C₂-repeat expansion in FTLD patients.

Economic burden of amyotrophic lateral sclerosis: a Canadian study of out-of-pocket expenses.

Mutation analysis of patients with neurodegenerative disorders using NeuroX array.

Identical twins with the C9orf72 repeat expansion are discordant for ALS.

Electrical impedance myography in the evaluation of the tongue musculature in amyotrophic lateral sclerosis.

The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients.

Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death.

Mutation analysis of CHCHD10 in different neurodegenerative diseases.

Jump from pre-mutation to pathologic expansion in C9orf72.

Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral sclerosis.

MTHFSD and DDX58 are novel RNA-binding proteins abnormally regulated in amyotrophic lateral sclerosis.

Profiling Speech and Pausing in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).

C9orf72 isoforms in Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration.

Predicting Speech Intelligibility Decline in Amyotrophic Lateral Sclerosis Based on the Deterioration of Individual Speech Subsystems.

Genetic and epigenetic study of ALS-discordant identical twins with double mutations in SOD1 and ARHGEF28.

Physician-assisted death: A Canada-wide survey of ALS health care providers.

Speech in ALS: Longitudinal Changes in Lips and Jaw Movements and Vowel Acoustics.

Speech Movement Measures as Markers of Bulbar Disease in Amyotrophic Lateral Sclerosis.

DNA methylation age-acceleration is associated with disease duration and age at onset in C9orf72 patients.

Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI).

TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics.

Dysregulation of chromatin remodelling complexes in amyotrophic lateral sclerosis.

Loss of CHCHD10-CHCHD2 complexes required for respiration underlies the pathogenicity of a CHCHD10 mutation in ALS.

Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis.

Clinical and neuropathological features of ALS/FTD with TIA1 mutations.

Unaffected mosaiccase: RNA foci, dipeptide proteins, but upregulated C9orf72 expression.

Motor unit number index and neurophysiological index as candidate biomarkers of presymptomatic motor neuron loss in amyotrophic lateral sclerosis.

Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study.

Clinical Reasoning: A 42-year-old man with unilateral leg weakness.

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.